Northwestern University Feinberg School of Medicine

Asher Center for the Study and Treatment of Depressive Disorders

Molecular Basis of Altered Drug Metabolism During Pregnancy (Study 1) (Retinoid)

Northwestern University IRB STU00204600

Principal Investigators: Katherine L. Wisner, MD MS (Department of Psychiatry), Emily Miller, MD MPH (Department of Obstetrics and Gynecology), Catherine Stika, MD (Department of Obstetrics and Gynecology), Laura Rasmussen-Torvik, PhD MPH (Epidemiology), Dr. Jody Ciolino, PhD (Department of Preventative Medicine)

Why is this research important?

The purpose of this research is to understand changes in a woman’s body during pregnancy, specifically how the body processes medication during pregnancy.

We know that over 90% of women take at least one drug during pregnancy. Because of the changes in a pregnant women’s body, processes such as the rate of drug metabolism can change over the course of the three trimesters.

Drug metabolism is controlled by certain genes in the body. This study will be examining the up-regulation, or “speeding up” of a certain enzyme in the liver called CYP2D6, which helps the body process many different drugs. We will measure compounds related to vitamin A (Retinoid), which we think might be involved in the process that speeds up the enzyme activity, in your blood.

The primary goal of our research is to understand how drug metabolism changes across pregnancy. The secondary goal is to define how the activity of enzymes in the liver are up-regulated (increased) during pregnancy. This research will help to build a knowledge base for the prediction of drug metabolism changes and the design of optimal individualized dosage regimens for pregnant women.

 You may be eligible to participate if you:

 What’s involved?

 Compensation Includes:

 If you are interested in participating or would like to hear more information, please contact our research team at gabrielle.mesches@northwestern.edu or 1-855-99-ASHER.